Pet Cancer Therapeutics Market

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.

Pet Cancer Therapeutics Market contains market size and forecasts of Pet Cancer Therapeutics in global, including the following market information:

Global Pet Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Pet Cancer Therapeutics Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Pet Cancer Therapeutics companies in 2021 (%)

The global Pet Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Pet Cancer Therapeutics include Aratana Therapeutics, Inc, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc, VetDC, Inc, Karyopharm Therapeutics, Inc, Rhizen Pharmaceutical SA and Regeneus Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Pet Cancer Therapeutics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Pet Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Pet Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Chemotherapy
• Targeted Therapy
• Combination Therapy
• Immunotherapy

Global Pet Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Pet Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary
• Squamous Cell Cancer
• Others

Global Pet Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Pet Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Pet Cancer Therapeutics revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Pet Cancer Therapeutics revenues share in global market, 2021 (%)
• Key companies Pet Cancer Therapeutics sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Pet Cancer Therapeutics sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Aratana Therapeutics, Inc
• AB Science
• Boehringer Ingelheim International GmbH
• Zenoaq
• Morphogenesis, Inc
• VetDC, Inc
• Karyopharm Therapeutics, Inc
• Rhizen Pharmaceutical SA
• Regeneus Ltd.
• Oasmia Pharmaceuticals AB
• Zoetis